Allurion Technologies, Inc. (ALUR) Stock Price
ALURStock
$0.47−61.28%52W
Market Cap$288,634.225
P/E—
PEG Ratio—
Div yield—
Beta-0.09
ALUR Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-105.75%
Price vs S&P 500 (4W)-53.44%
VGM Score36.59
ALUR Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q1 2026 | -$5.10 | -$6.90 | -35.29%(-$1.80) | |
| Q4 2025 | -$9.45 | -$5.44 | +42.44%(+$4.01) | |
| Q3 2025 | -$36.75 | -$17.75 | +51.69%(+$19.00) | |
| Q2 2025 | -$13.35 | -$13.10 | +1.90%(+$0.25) |
ALUR Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.25
4.29
4.29
4.29
Industry Peers — Surgical & Medical Instruments(142)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|---|---|---|
ALURAllurion Technologies, Inc. | A | F | F | 0.0x | — | 52.7% | -216.5% | $0.47 |
| SYKStryker Corporation | C | B | C | 4.4x | 11.8% | 65.3% | 21.3% | $294.66 |
| MMM3M Company | C | D | B | 3.4x | -5.0% | 39.4% | 18.4% | $164.75 |
| BSXBoston Scientific Corp. | C | B | C | 3.1x | 15.2% | 69.5% | 19.8% | $44.39 |
| BDXBecton, Dickinson and Co. | B | D | A | 2.5x | 6.3% | 46.7% | 9.6% | $191.75 |
| MDLNMedline Inc. Class A common stock | C | D | C | 1.6x | — | 26.2% | 6.0% | $35.96 |
| RMDResMed Inc. | C | C | B | 5.9x | 12.1% | 61.1% | 33.4% | $238.97 |
| DXCMDexCom, Inc. | C | B | B | 6.5x | 19.3% | 64.3% | 22.9% | $86.04 |
| WSTWest Pharmaceutical Services, Inc. | D | C | A | 8.5x | 7.4% | 36.8% | 20.4% | $384.02 |
| SOLVSolventum Corporation | C | C | B | 1.8x | — | 54.8% | 23.9% | $85.81 |
| BAXBaxter International Inc. | B | D | B | 1.1x | -0.8% | 30.7% | -2.3% | $25.28 |
About Allurion Technologies, Inc.
Allurion Technologies develops a minimally invasive weight loss platform centered on the Allurion Balloon, a swallowable intragastric balloon that requires no surgery, endoscopy, or anesthesia. The platform combines the proprietary balloon with AI-powered remote patient monitoring, a behavior modification program, and virtual care services delivered through its proprietary Allurion VCS. This non-procedural approach addresses a significant market opportunity in weight management for overweight patients seeking alternatives to invasive interventions.